[go: up one dir, main page]

DK2844222T3 - Lægemiddelformulering med forsinket udløsning - Google Patents

Lægemiddelformulering med forsinket udløsning Download PDF

Info

Publication number
DK2844222T3
DK2844222T3 DK13723033T DK13723033T DK2844222T3 DK 2844222 T3 DK2844222 T3 DK 2844222T3 DK 13723033 T DK13723033 T DK 13723033T DK 13723033 T DK13723033 T DK 13723033T DK 2844222 T3 DK2844222 T3 DK 2844222T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulation
delayed delivery
delayed
delivery
formulation
Prior art date
Application number
DK13723033T
Other languages
English (en)
Inventor
Thomas Buser
Frédéric Jean-Claude Goutte
Abdul Waseh Basit
Felipe José Oliveria Varum
Ana Cristina Freire
González Roberto Carlos Bravo
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2844222(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Application granted granted Critical
Publication of DK2844222T3 publication Critical patent/DK2844222T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Grain Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK13723033T 2012-04-30 2013-04-29 Lægemiddelformulering med forsinket udløsning DK2844222T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261640217P 2012-04-30 2012-04-30
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation
PCT/EP2013/058923 WO2013164316A1 (en) 2012-04-30 2013-04-29 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
DK2844222T3 true DK2844222T3 (da) 2019-12-09

Family

ID=46025554

Family Applications (5)

Application Number Title Priority Date Filing Date
DK12166110.2T DK2659881T3 (da) 2012-04-30 2012-04-30 Lægemiddelformulering med forsinket udløsning
DK17188821.7T DK3278792T3 (da) 2012-04-30 2013-04-29 Lægemiddelformulering med forsinket udløsning
DK13719543.4T DK2844220T3 (da) 2012-04-30 2013-04-29 Lægemiddelformulering med forsinket udløsning
DK13723033T DK2844222T3 (da) 2012-04-30 2013-04-29 Lægemiddelformulering med forsinket udløsning
DK17156227.5T DK3189830T3 (da) 2012-04-30 2013-04-29 Lægemiddelformulering med forsinket udløsning

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK12166110.2T DK2659881T3 (da) 2012-04-30 2012-04-30 Lægemiddelformulering med forsinket udløsning
DK17188821.7T DK3278792T3 (da) 2012-04-30 2013-04-29 Lægemiddelformulering med forsinket udløsning
DK13719543.4T DK2844220T3 (da) 2012-04-30 2013-04-29 Lægemiddelformulering med forsinket udløsning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17156227.5T DK3189830T3 (da) 2012-04-30 2013-04-29 Lægemiddelformulering med forsinket udløsning

Country Status (41)

Country Link
US (6) US9364440B2 (da)
EP (6) EP2659881B1 (da)
JP (2) JP6621662B2 (da)
KR (6) KR102177773B1 (da)
CN (5) CN106983735A (da)
AR (1) AR090898A1 (da)
AU (4) AU2013255914B2 (da)
BR (3) BR122019022551B1 (da)
CA (4) CA2871016C (da)
CL (2) CL2014002795A1 (da)
CO (2) CO7141433A2 (da)
CR (4) CR20190245A (da)
CU (1) CU24304B1 (da)
CY (4) CY1120215T1 (da)
DK (5) DK2659881T3 (da)
EA (2) EA032514B1 (da)
ES (6) ES2655622T3 (da)
GE (4) GEP201706736B (da)
HR (2) HRP20180068T1 (da)
HU (5) HUE036187T2 (da)
JO (6) JOP20200144A1 (da)
LT (5) LT2659881T (da)
ME (2) ME03364B (da)
MX (4) MX373249B (da)
MY (3) MY169161A (da)
NO (1) NO2659881T3 (da)
NZ (3) NZ629260A (da)
PE (3) PE20150129A1 (da)
PH (2) PH12014502340B1 (da)
PL (5) PL2659881T3 (da)
PT (5) PT2659881T (da)
RS (5) RS56839B1 (da)
SA (2) SA113340508B1 (da)
SG (2) SG11201406799XA (da)
SI (5) SI2659881T1 (da)
SM (5) SMT201800095T1 (da)
TN (2) TN2014000442A1 (da)
TR (3) TR201905226T4 (da)
TW (3) TWI618547B (da)
UY (1) UY34772A (da)
WO (2) WO2013164315A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20192210T1 (hr) * 2012-04-30 2020-02-21 Tillotts Pharma Ag Formulacija lijeka s produženim otpuštanjem
DK2659881T3 (da) 2012-04-30 2018-02-05 Tillotts Pharma Ag Lægemiddelformulering med forsinket udløsning
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
CN105025888B (zh) * 2013-02-22 2018-10-12 志瑞亚新药工业株式会社 肠溶片
WO2015062640A1 (en) 2013-10-29 2015-05-07 Tillotts Pharma Ag A delayed release drug formulation
US10517869B2 (en) 2013-12-24 2019-12-31 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
EP3302703B1 (en) 2015-06-01 2021-08-25 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
US11311573B2 (en) * 2016-11-30 2022-04-26 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
IL277496B2 (en) * 2018-03-23 2025-01-01 Palatin Technologies Inc Melanocortin receptor-specific peptide formulations and methods for specific administration to the gastrointestinal tract
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
ES2994844T3 (en) 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662901B1 (en) 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
HUE057346T2 (hu) * 2018-12-10 2022-05-28 Aphaia Ip Ag Orális gyógyászati adagolási forma metabolikus rendellenességek és rokon betegségek enterokinek megtervezett felszabadításával történõ kezelésére
CN111617047B (zh) * 2019-02-27 2021-06-22 广州喜鹊医药有限公司 一种含tbn或其盐或其水合物的药物组合物及其制备方法
GB201905940D0 (en) * 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
MX2022001865A (es) * 2019-08-12 2022-03-11 Massachusetts Inst Technology Articulos y metodos para la administracion de agentes terapeuticos.
CN115461046A (zh) * 2019-11-13 2022-12-09 爱的发制药集团 用于生产具有结肠递送的口服施用药物组合物的方法
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
JP7764378B2 (ja) * 2020-07-13 2025-11-05 キリンホールディングス株式会社 フィルムコーティング錠剤
EP4346858A4 (en) * 2021-06-01 2025-06-18 NBI Biosciences Pvt Ltd Microbially triggered oral intestinal drug delivery formulation and method for producing the same
CN117024341A (zh) * 2022-04-30 2023-11-10 宁波大学 一类d-2a不对称型热活化延迟荧光材料的合成及其应用
CN116898823A (zh) * 2023-08-02 2023-10-20 中国农业大学 一种微囊结构及其制备方法和应用
TW202535385A (zh) * 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 必托里賽（ｐｉｔｏｌｉｓａｎｔ）之新穎調配物及使用方法
CN118806729B (zh) * 2024-06-18 2025-04-22 海南合瑞制药股份有限公司 美沙拉秦肠溶缓释微丸及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) * 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
KR0157280B1 (ko) * 1992-11-06 1998-11-16 나까토미 히로타카 하부소화관 방출성의 경구의약제제
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
PT1108431E (pt) * 1999-12-16 2003-08-29 Medinfar Produtos Farmaceutico Preparacoes farmaceuticas gastro-resistentes multiunitarias contendo piroxicam
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780A7 (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CN1293867C (zh) 2001-05-25 2007-01-10 爱诗爱诗制药株式会社 药物复合制剂
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
CA2558535A1 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1904039A2 (en) 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
US20090175935A1 (en) 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
WO2008068584A2 (en) * 2006-12-05 2008-06-12 University Of Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
JPWO2008117814A1 (ja) * 2007-03-26 2010-07-15 帝國製薬株式会社 大腸送達用経口製剤
HUE046488T2 (hu) * 2007-05-07 2020-03-30 Evonik Operations Gmbh Gyorsított drogfelszabadulást biztosító, bélben oldódó bevonatot tartalmazó szilárd adagolási forma
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) * 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
SI2443246T1 (en) 2009-06-15 2018-05-31 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
WO2011049309A2 (ko) * 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
WO2012075015A2 (en) 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
WO2013035081A2 (de) 2011-09-07 2013-03-14 JÄNISCH, Melisa Optimale formulierung zur freisetzung eines wirkstoffes im dickdarm
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
DK2659881T3 (da) 2012-04-30 2018-02-05 Tillotts Pharma Ag Lægemiddelformulering med forsinket udløsning
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
WO2015062640A1 (en) 2013-10-29 2015-05-07 Tillotts Pharma Ag A delayed release drug formulation

Also Published As

Publication number Publication date
JOP20200146A1 (ar) 2022-10-30
WO2013164315A1 (en) 2013-11-07
US10226430B2 (en) 2019-03-12
NO2659881T3 (da) 2018-04-28
RS57431B1 (sr) 2018-09-28
KR20200075024A (ko) 2020-06-25
EA201491783A1 (ru) 2014-12-30
TR201903569T4 (tr) 2019-04-22
PH12014502339B1 (en) 2014-12-22
AU2017210571B2 (en) 2018-11-29
RS59697B1 (sr) 2020-01-31
US20150125525A1 (en) 2015-05-07
KR102104070B1 (ko) 2020-04-24
NZ725409A (en) 2018-05-25
US20170266117A1 (en) 2017-09-21
DK2659881T3 (da) 2018-02-05
US9364440B2 (en) 2016-06-14
PL3189830T3 (pl) 2018-11-30
TR201905226T4 (tr) 2019-05-21
EP3187171C0 (en) 2024-09-25
MY190392A (en) 2022-04-20
KR102102198B1 (ko) 2020-04-21
ES2655622T3 (es) 2018-02-20
JP6621662B2 (ja) 2019-12-18
CN104302274A (zh) 2015-01-21
ES2714448T3 (es) 2019-05-28
US9814681B2 (en) 2017-11-14
CN110237056A (zh) 2019-09-17
US20170035698A1 (en) 2017-02-09
MX2014012887A (es) 2015-05-08
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (en) 2018-03-30
CA3052460A1 (en) 2013-11-07
TN2014000441A1 (en) 2016-03-30
PT3278792T (pt) 2019-05-23
AU2013255914A1 (en) 2014-11-13
PE20150129A1 (es) 2015-02-13
SI3278792T1 (sl) 2019-06-28
EP2844222B1 (en) 2019-11-13
EA032514B1 (ru) 2019-06-28
NZ629262A (en) 2017-01-27
CL2014002795A1 (es) 2015-02-13
JOP20200148B1 (ar) 2023-09-17
JO3574B1 (ar) 2020-07-05
EP3189830A1 (en) 2017-07-12
BR112014026933A2 (pt) 2017-06-27
JP2015515964A (ja) 2015-06-04
ME03364B (me) 2019-10-20
SMT202000014T1 (it) 2020-03-13
MX366677B (es) 2019-07-19
AU2013255913A1 (en) 2014-11-13
RS58625B1 (sr) 2019-05-31
BR122019022551B1 (pt) 2022-07-19
CN104271113A (zh) 2015-01-07
SI3189830T1 (en) 2018-08-31
PT3189830T (pt) 2018-10-19
AU2017210577B2 (en) 2018-11-29
EP2844220B1 (en) 2019-01-23
JOP20200147A1 (ar) 2022-10-30
PT2659881T (pt) 2018-01-29
JOP20200145A1 (ar) 2022-10-30
CA2871017A1 (en) 2013-11-07
CO7151506A2 (es) 2014-12-29
KR102177773B1 (ko) 2020-11-12
HUE042833T2 (hu) 2019-07-29
TN2014000442A1 (en) 2016-03-30
CR20190245A (es) 2019-07-29
CA2871016C (en) 2023-03-21
GEP201706758B (en) 2017-10-25
US10272048B2 (en) 2019-04-30
CN110237056B (zh) 2022-03-08
HUE046628T2 (hu) 2020-03-30
US20200214987A1 (en) 2020-07-09
TR201809416T4 (tr) 2018-07-23
HRP20180965T1 (hr) 2018-08-10
KR20200073296A (ko) 2020-06-23
ES2987408T3 (es) 2024-11-14
ES2720258T3 (es) 2019-07-19
BR112014026935A2 (pt) 2017-06-27
CN110200949A (zh) 2019-09-06
EA032811B1 (ru) 2019-07-31
EP2844220A1 (en) 2015-03-11
EP3187171B1 (en) 2024-09-25
ES2761341T3 (es) 2020-05-19
EP3278792A1 (en) 2018-02-07
MX373249B (es) 2020-05-12
AR090898A1 (es) 2014-12-17
HUE037702T2 (hu) 2018-09-28
CY1122475T1 (el) 2021-01-27
CA3080035A1 (en) 2013-11-07
EP2844222A1 (en) 2015-03-11
CU24304B1 (es) 2018-01-10
WO2013164316A1 (en) 2013-11-07
SI2844222T1 (sl) 2020-02-28
SI2844220T1 (sl) 2019-05-31
SA115370043B1 (ar) 2016-05-24
CR20140486A (es) 2015-01-19
ES2673931T3 (es) 2018-06-26
CL2014002796A1 (es) 2015-02-06
CA2871016A1 (en) 2013-11-07
KR20150004910A (ko) 2015-01-13
JP2015515965A (ja) 2015-06-04
CY1120215T1 (el) 2018-12-12
CN106983735A (zh) 2017-07-28
RS58735B1 (sr) 2019-06-28
HUE043238T2 (hu) 2019-08-28
US11517534B2 (en) 2022-12-06
BR112014026933B1 (pt) 2022-07-19
TWI705833B (zh) 2020-10-01
PL2659881T3 (pl) 2018-05-30
PT2844220T (pt) 2019-03-27
UY34772A (es) 2013-11-29
PL2844222T3 (pl) 2020-03-31
TWI700102B (zh) 2020-08-01
AU2013255913B2 (en) 2017-08-31
PE20190625A1 (es) 2019-04-26
MX367127B (es) 2019-08-06
PH12014502339A1 (en) 2014-12-22
HUE036187T2 (hu) 2018-06-28
JOP20200146B1 (ar) 2023-09-17
US20140056980A1 (en) 2014-02-27
JOP20200148A1 (ar) 2022-10-30
PH12014502340A1 (en) 2014-12-22
EA201491781A1 (ru) 2014-12-30
CN110200949B (zh) 2021-11-16
JOP20200147B1 (ar) 2023-09-17
PL3278792T3 (pl) 2019-09-30
CA3052460C (en) 2022-06-07
CR20140485A (es) 2015-01-19
ME03641B (me) 2020-07-20
CU20140123A7 (es) 2015-02-26
SG11201406799XA (en) 2014-11-27
KR20150004911A (ko) 2015-01-13
CY1120492T1 (el) 2019-07-10
CO7141433A2 (es) 2014-12-12
LT3189830T (lt) 2018-07-10
LT2659881T (lt) 2018-02-12
EP2659881A1 (en) 2013-11-06
DK3278792T3 (da) 2019-05-06
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
EP3278792B1 (en) 2019-02-20
CY1121609T1 (el) 2020-05-29
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
DK3189830T3 (da) 2018-07-16
DK2844220T3 (da) 2019-04-08
GEP201706759B (en) 2017-10-25
SMT201900252T1 (it) 2019-07-11
CR20190246A (es) 2019-09-03
LT3278792T (lt) 2019-05-10
GEP201706736B (en) 2017-09-25
LT2844220T (lt) 2019-04-10
AU2017210577A1 (en) 2017-08-24
EP3189830B1 (en) 2018-05-23
NZ629260A (en) 2017-01-27
AU2017210571A1 (en) 2017-08-24
SMT201800360T1 (it) 2018-09-13
EP3187171A1 (en) 2017-07-05
JOP20200144A1 (ar) 2017-06-16
JOP20200145B1 (ar) 2023-09-17
MY169161A (en) 2019-02-19
US11534406B2 (en) 2022-12-27
TWI618547B (zh) 2018-03-21
US20150132380A1 (en) 2015-05-14
SMT201800095T1 (it) 2018-03-08
MX362529B (es) 2019-01-23
PE20142442A1 (es) 2015-01-28
TW201720430A (zh) 2017-06-16
SMT201900215T1 (it) 2019-05-10
LT2844222T (lt) 2019-12-27
TW201343202A (zh) 2013-11-01
AU2013255914B2 (en) 2017-08-31
RS56839B1 (sr) 2018-04-30
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
PH12014502340B1 (en) 2014-12-22
TW202037370A (zh) 2020-10-16
GEP201706753B (en) 2017-10-25
KR20190127984A (ko) 2019-11-13
KR20190127986A (ko) 2019-11-13
CN104271113B (zh) 2019-03-22
SG11201406798WA (en) 2014-11-27
JP6621661B2 (ja) 2019-12-18
PT2844222T (pt) 2019-12-30

Similar Documents

Publication Publication Date Title
DK2844222T3 (da) Lægemiddelformulering med forsinket udløsning
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
DK2694038T3 (da) Farmaceutisk sammensætning
ZA201406233B (en) Pharmaceutical composition and administration thereof
DK3639872T3 (da) Lægemiddeladministrationsanordning
DK2768559T3 (da) Lægemiddelindgivelsesanordning
BR112015002738A2 (pt) composto , e , composição farmacêutica
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
DK2740504T3 (da) Lægemiddelfremføringsanordning
BR112013014644A2 (pt) composição farmacêutica e complexo
DK2897594T3 (da) Farmaceutisk sammensætning
DK2868318T3 (da) Injicerbar formulering
ZA201409020B (en) Pharmaceutical formulation
BR112014015885A8 (pt) preparação farmacêutica
ZA201405797B (en) Pharmaceutical dosage form
AP2015008208A0 (en) Pharmaceutical administration forms comprising
HUE039907T2 (hu) Gyógyszer-szállító technológia
EP2883547A4 (en) MEDICINE
IL235830A0 (en) New dosage and formulation
ZA201405925B (en) Pharmaceutical formulation having improved stability
DK3473255T3 (da) Farmaceutisk formulering omfattende ciclesonid
BR112015002646A2 (pt) composto e composição farmacêutica
BR112013033052A2 (pt) formulações de entrega de fármaco
CO6990712A2 (es) Combinación farmacéutica antineuritica y composiciones
DK2983747T3 (da) Lægemiddelindgivelsesindretning